|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Charles M. Baum||Pres, CEO & Director||1,01M||N/D||1958|
|Dr. James G. Christensen||Chief Scientific Officer & Exec. VP||655k||N/D||1968|
|Mr. Daniel R. Faga||Exec. VP, COO & Principal Financial Officer||N/D||N/D||1980|
|Ms. Vickie S. Reed||Sr. VP of Technical Operation & Chief Accounting Officer||N/D||N/D||1962|
|Mr. Philip Roberts||Sr. VP of Technical Operations||N/D||N/D||N/D|
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. It also develops mocetinostat, an orally investigational selective Class I and IV histone deacetylase inhibitor that has completed Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a Clinical Collaboration Agreement with Novartis International AG. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
L'ISS Governance QualityScore di Mirati Therapeutics, Inc. al 8 dicembre 2019 è 5. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 6; diritti degli azionisti: 4; retribuzione: 8.